source
- Moderna reports Q1 revenue surge driven by international COVID vaccine sales despite larger net lossModerna posted first‑quarter revenue of $389 million, more than triple the same period a year earlier, primarily from overseas COVID‑19 vaccine sales. The company recorded a net loss of $1.3 billi…
- Seaport and Hemab price IPOs as Avalyn soars on Nasdaq debutThree biotechnology companies announced the pricing of their initial public offerings between Thursday and Friday, collectively targeting more than $850 million in proceeds. Seaport Therapeutics a…